Currently, a study found that insertion of HPV-E6 in engineered exosomes induced CD8+ T cell immunity against a tumor-associated antigen, a finding which demonstrated a putative anti-tumor therapeutic approach in a preclinical model (Manfredi et al., 2016). This evidence concerns the gene CD8A and neoplasm.